Detection of prostate-specific antigen immunoreactivity in breast tumors

Breast Cancer Research and Treatment

Volumn 32, Issue 3, 1994, Pages 301-310

  Diamandis, Eleftherios P ^a,b   Yu, He ^a,b   Sutherland, Donald J A ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

breast cancer; prognostic markers; prostate specific antigen; steroid hormone receptors

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; FEMALE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR SUPPRESSOR GENE;

AGE FACTORS; BREAST NEOPLASMS; FEMALE; HUMAN; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROTEIN P53; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SUPPORT, NON-U.S. GOV'T;

EID: 0027975428     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/BF00666007     Document Type: Article

References (29)

1. The prostate: an increasing medical problem
2. Prostate cancer: a current perspective
3. The endocrinology and treatment of prostate tumor progression
4. Growth factors and oncogenes in prostate cancer
5. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
6. Immunoassays with time-resolved fluorescence spectroscopy. Principles and applications
7. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies
8. Breast cancer, (first of three parts)
9. Breast cancer, (second of three parts)
10. Breast cancer, (third of three parts)
11. Prognostic factors and treatment decisions in axillary node-negative breast cancer
12. How to use prognostic factors in axillary nodenegative breast cancer patients
13. Endocrine therapy for advanced breast cancer: a review
14. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry
15. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostatespecific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer
16. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin
17. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice
18. Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumors
19. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
20. Androgen receptors in breast cancer
21. Transcriptional regulation of prostate kallikrein-like gene by androgen
22. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA) but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line
23. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostate adenocarcinoma cell line, LNCaP
24. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostate hyperplasia
25. Transcriptional activation of the estrogen receptor
26. The oestrogen-regulated pS2-BCEI protein in breast cancer
27. Prediction of relapse and survival in breast cancer patients by pS2 protein status
28. Cathepsin D in breast cancer
29. p53 and cathepsin D are independent of established prognostic factors in breast cancer